Dr. Michael J. Pishvaian
Claim this profileSibley Memorial Hospital
Area of expertise
Pancreatic Cancer
Michael J. Pishvaian has run 10 trials for Pancreatic Cancer. Some of their research focus areas include:
Solid Tumors
Michael J. Pishvaian has run 5 trials for Solid Tumors. Some of their research focus areas include:
Affiliated Hospitals
Sibley Memorial Hospital
Johns Hopkins Sibley Memorial Hospital
Clinical Trials Michael J. Pishvaian is currently running
Olaparib
for Pancreatic Cancer
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
Recruiting
0 awards
Phase 2
32 criteria
Perioperative Chemotherapy
for Pancreatic Cancer
This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).
Recruiting
4 awards
Phase 3
18 criteria
More about Michael J. Pishvaian
Clinical Trial Related
4 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 6 Active Clinical Trials
Treatments Michael J. Pishvaian has experience with
- Pembrolizumab
- Oxaliplatin
- Olaparib
- Hypofractionated Radiation Therapy
- Fluorouracil
- Irinotecan
Breakdown of trials Michael J. Pishvaian has run
Pancreatic Cancer
Solid Tumors
Colorectal Cancer
Stomach Cancer
Soft Tissue Sarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael J. Pishvaian specialize in?
Michael J. Pishvaian focuses on Pancreatic Cancer and Solid Tumors. In particular, much of their work with Pancreatic Cancer has involved Stage IV patients, or patients who are Stage III.
Is Michael J. Pishvaian currently recruiting for clinical trials?
Yes, Michael J. Pishvaian is currently recruiting for 6 clinical trials in Washington District of Columbia. If you're interested in participating, you should apply.
Are there any treatments that Michael J. Pishvaian has studied deeply?
Yes, Michael J. Pishvaian has studied treatments such as Pembrolizumab, Oxaliplatin, Olaparib.
What is the best way to schedule an appointment with Michael J. Pishvaian?
Apply for one of the trials that Michael J. Pishvaian is conducting.
What is the office address of Michael J. Pishvaian?
The office of Michael J. Pishvaian is located at: Sibley Memorial Hospital, Washington, District of Columbia 20016 United States. This is the address for their practice at the Sibley Memorial Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.